Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

29.21 -0.05 (-0.19%)

Streaming Delayed Price Updated: 12:47 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Genmab A/S - American Depositary Shares

< Previous 1 2 3 Next >

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 16, 2026

From Genmab A/S

Via Business Wire

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

January 07, 2026

From Genmab A/S

Via Business Wire

Genmab Portfolio Prioritization Update

December 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

December 08, 2025

From Genmab A/S

Via Business Wire

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

December 07, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

December 06, 2025

From Genmab A/S

Via Business Wire

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 18, 2025

From Genmab A/S

Via Business Wire

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Genmab A/S

Via Business Wire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

October 18, 2025

From Genmab

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

October 07, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

September 29, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 03, 2025

From Genmab A/S

Via Business Wire

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

August 26, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

August 07, 2025

From Genmab

Via Business Wire

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15, 2025

From Genmab

Via Business Wire

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

June 02, 2025

From Genmab A/S

Via Business Wire

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

From Genmab A/S

Via Business Wire

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025

From Genmab A/S

Via Business Wire

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 01, 2025

From Genmab A/S

Via Business Wire

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

March 31, 2025

From Genmab A/S

Via Business Wire

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

March 27, 2025

From Genmab A/S

Via Business Wire

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

March 17, 2025

From Genmab

Via Business Wire

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

March 10, 2025

From Genmab A/S

Via Business Wire

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

February 20, 2025

From Genmab A/S

Via Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

December 08, 2024

From Genmab A/S

Via Business Wire

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

December 09, 2024

From Genmab A/S

Via Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

December 07, 2024

From Genmab A/S

Via Business Wire

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

November 05, 2024

From Genmab A/S

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.